AU2015310909B2 - Recombinant modified vaccinia virus Ankara (MVA) filovirus vaccine - Google Patents

Recombinant modified vaccinia virus Ankara (MVA) filovirus vaccine Download PDF

Info

Publication number
AU2015310909B2
AU2015310909B2 AU2015310909A AU2015310909A AU2015310909B2 AU 2015310909 B2 AU2015310909 B2 AU 2015310909B2 AU 2015310909 A AU2015310909 A AU 2015310909A AU 2015310909 A AU2015310909 A AU 2015310909A AU 2015310909 B2 AU2015310909 B2 AU 2015310909B2
Authority
AU
Australia
Prior art keywords
mva
leu
thr
seq
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015310909A
Other languages
English (en)
Other versions
AU2015310909A1 (en
Inventor
Ulrike DIRMEIER
Jurgen Hausmann
Hubertus Hochrein
Henning Lauterbach
Robin Steigerwald
Ariane Volkmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Bavarian Nordic AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic AS filed Critical Bavarian Nordic AS
Publication of AU2015310909A1 publication Critical patent/AU2015310909A1/en
Application granted granted Critical
Publication of AU2015310909B2 publication Critical patent/AU2015310909B2/en
Priority to AU2021209228A priority Critical patent/AU2021209228A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015310909A 2014-09-03 2015-09-03 Recombinant modified vaccinia virus Ankara (MVA) filovirus vaccine Active AU2015310909B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021209228A AU2021209228A1 (en) 2014-09-03 2021-07-28 Recombinant modified vaccinia virus Ankara (MVA) filovirus vaccine

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462045538P 2014-09-03 2014-09-03
US62/045,538 2014-09-03
US201462055154P 2014-09-25 2014-09-25
US62/055,154 2014-09-25
PCT/EP2015/070161 WO2016034678A2 (en) 2014-09-03 2015-09-03 Recombinant modified vaccinia virus ankara (mva) filovirus vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021209228A Division AU2021209228A1 (en) 2014-09-03 2021-07-28 Recombinant modified vaccinia virus Ankara (MVA) filovirus vaccine

Publications (2)

Publication Number Publication Date
AU2015310909A1 AU2015310909A1 (en) 2017-03-02
AU2015310909B2 true AU2015310909B2 (en) 2021-05-27

Family

ID=54145734

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015310909A Active AU2015310909B2 (en) 2014-09-03 2015-09-03 Recombinant modified vaccinia virus Ankara (MVA) filovirus vaccine
AU2021209228A Abandoned AU2021209228A1 (en) 2014-09-03 2021-07-28 Recombinant modified vaccinia virus Ankara (MVA) filovirus vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021209228A Abandoned AU2021209228A1 (en) 2014-09-03 2021-07-28 Recombinant modified vaccinia virus Ankara (MVA) filovirus vaccine

Country Status (14)

Country Link
US (2) US10576141B2 (enExample)
EP (1) EP3188752A2 (enExample)
JP (2) JP6823586B2 (enExample)
KR (2) KR102736868B1 (enExample)
CN (2) CN106999565B (enExample)
AU (2) AU2015310909B2 (enExample)
CA (1) CA2959105C (enExample)
IL (2) IL250552B (enExample)
MX (1) MX2017002791A (enExample)
MY (1) MY193417A (enExample)
SG (2) SG10201901735XA (enExample)
UA (1) UA126848C2 (enExample)
WO (1) WO2016034678A2 (enExample)
ZA (1) ZA201701077B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
WO2013032942A1 (en) 2011-08-26 2013-03-07 Yoshihiro Kawaoka Influenza viruses with mutant pb2 gene segment as live attenuated vaccines
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
MX379069B (es) 2014-11-04 2025-03-10 Janssen Vaccines & Prevention Bv Vacunas terapeuticas contra el vph16.
ES2920773T3 (es) * 2014-11-26 2022-08-09 Neuravi Ltd Un dispositivo de extracción de coágulos para eliminar un coágulo oclusivo de un vaso sanguíneo
US11701418B2 (en) 2015-01-12 2023-07-18 Geovax, Inc. Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)
JP2018510143A (ja) * 2015-02-25 2018-04-12 メモリアル スローン ケタリング キャンサー センター 不活化非複製改変ワクシニアウイルスアンカラ（ｍｖａ）の固形腫瘍のための単独療法又は免疫チェックポイント遮断剤併用における使用
JP2018512856A (ja) 2015-04-17 2018-05-24 アルパイン イミューン サイエンシズ インコーポレイテッド 調整可能な親和性を有する免疫調節タンパク質
CA3011014A1 (en) * 2016-01-08 2017-07-13 Harriet Robinson Compositions and methods for generating an immune response to a tumor associated antigen
WO2017136419A1 (en) 2016-02-03 2017-08-10 Geovax Inc. Compositions and methods for generating an immune response to a flavivirus
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
US10882914B2 (en) 2016-04-15 2021-01-05 Alpine Immune Sciences, Inc. ICOS ligand variant immunomodulatory proteins and uses thereof
KR102764225B1 (ko) 2016-04-15 2025-02-07 알파인 이뮨 사이언시즈, 인코포레이티드 Cd80 변이체 면역조절 단백질 및 그의 용도
MX2018013340A (es) * 2016-05-02 2019-08-21 Janssen Vaccines & Prevention Bv Combinaciones de vacunas terapeuticas para el vph.
EP3484507A1 (en) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
EP3529361B1 (en) * 2016-10-20 2021-03-24 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
KR20190141146A (ko) 2017-03-16 2019-12-23 알파인 이뮨 사이언시즈, 인코포레이티드 Pd-l2 변이체 면역조절 단백질 및 그의 용도
MX2019010887A (es) 2017-03-16 2019-10-15 Alpine Immune Sciences Inc Proteinas inmunomoduladoras de cb80 variante y usos de estas.
EP3606553A1 (en) 2017-04-06 2020-02-12 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
EP3624851A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3624845A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
US20200171141A1 (en) * 2017-07-18 2020-06-04 Geovax, Inc. Compositions and Methods for Generating an Immune Response to LASV
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
GB201716181D0 (en) * 2017-10-04 2017-11-15 Univ Cape Town Recombinant mva with modified hiv-1 env
EP4442268A3 (en) 2017-10-10 2025-04-02 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
WO2019079520A2 (en) 2017-10-18 2019-04-25 Alpine Immune Sciences, Inc. ICOS VARIANT LIGAND IMMUNOMODULATORY IMMUNOMODULATORY PROTEINS, COMPOSITIONS AND METHODS THEREOF
JP2021500891A (ja) 2017-10-25 2021-01-14 ウィスコンシン アルムニ リサーチ ファンデイション 卵における複製のための安定化されたｈａを有する組換えインフルエンザウイルス
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
US12150988B2 (en) 2018-09-06 2024-11-26 Bavarian Nordic A/S Storage improved poxvirus compositions
JP2022513326A (ja) * 2018-09-28 2022-02-07 ケンブリッジ エンタープライズ リミテッド ワクチンおよび方法
JP7662157B2 (ja) 2019-02-08 2025-04-15 ウィスコンシン アルムニ リサーチ ファンデイション ヒト化細胞系
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
EP4022046A2 (en) 2019-08-27 2022-07-06 Wisconsin Alumni Research Foundation (WARF) Recombinant influenza viruses with stabilized ha for replication in eggs
EP4093415A1 (en) 2020-01-24 2022-11-30 Wisconsin Alumni Research Foundation (WARF) Recombinant influenza viruses with stabilized na
KR20220153587A (ko) 2020-03-12 2022-11-18 버베리안 노딕 에이/에스 폭스바이러스 안정성을 개선하는 조성물
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
CN115819616B (zh) * 2021-07-28 2025-04-11 江苏瑞科生物技术股份有限公司 一种基因重组vzv融合蛋白及其制备方法和应用
AU2024236322A1 (en) 2023-03-10 2025-08-21 Bavarian Nordic A/S Methods of isolating poxviruses from avian cell cultures
IL322961A (en) 2023-03-10 2025-10-01 Bavarian Nordic As Production of smallpox viruses from cell cultures
WO2024188801A1 (en) 2023-03-10 2024-09-19 Bavarian Nordic A/S Use of quail cell lines for poxvirus production

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014037124A1 (en) * 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1586331B1 (en) * 2001-10-01 2008-05-28 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health Development of a preventive vaccine for filovirus infection in primates
WO2003028632A2 (en) * 2001-10-01 2003-04-10 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Development of a preventive vaccine for filovirus infection in primates
US20060088909A1 (en) * 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
WO2006037038A1 (en) * 2004-09-27 2006-04-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Optimized vaccines to provide protection against ebola and other viruses
GB0706912D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines
EP3351628B1 (en) * 2008-10-24 2023-07-26 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services Human ebola virus species and compositions and methods thereof
WO2010057650A1 (en) * 2008-11-21 2010-05-27 Bavarian Nordic A/S Vector comprising multiple homologous nucleotide sequences
WO2011071574A2 (en) * 2009-09-02 2011-06-16 United States Deparment Of The Army, As Represented By The Secretary Of The Army Monoclonal antibodies against glycoprotein of ebola sudan boniface virus
EP3466440A1 (en) 2010-04-16 2019-04-10 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Chimpanzee adenoviral vector-based filovirus vaccines
EP4190350A1 (en) * 2012-04-12 2023-06-07 The Trustees Of The University Of Pennsylvania Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
GB201303406D0 (en) 2013-02-26 2013-04-10 Health Prot Agency Crimean-Congo Haemorrhagic Fever Virus Antigenic Composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014037124A1 (en) * 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HENNING LAUTERBACH ET AL, "Genetic Adjuvantation of Recombinant MVA with CD40L Potentiates CD8 T Cell Mediated Immunity", FRONTIERS IN IMMUNOLOGY, (2013-01-01), vol. 4, doi:10.3389/fimmu.2013.00251, ISSN 1664-3224 *
HODGE J W ET AL, VACCINE, vol. 27, no. 33, (2009), pages 4475 - 4482 *
HUTCHINGS, CL ET AL, "Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge", INFECTION AND IMMUNITY, (2007), vol. 75, no. 12, pages 5819 - 5826 *
K. L. WARFIELD ET AL, "Advances in Virus-Like Particle Vaccines for Filoviruses", JOURNAL OF INFECTIOUS DISEASES (2011), vol. 20432-46, 90, 91, 92-100, no. suppl 3, pages S1053 - S1059 *
KEEFER, MC ET AL, "A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects", VACCINE, vol. 29, no. 10, (2010), pages 1948 - 1958 *
RIMMELZWAAN G F ET AL, "Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara", EXPERT REVIEW OF VACCINES, FUTURE DRUGS (2009), vol. 8, no. 4, pages 447 - 454 *
SOPRANA, E. ET AL, "Joint production of prime/boost pairs of Fowlpox Virus and Modified Vaccinia Ankara recombinants carrying the same transgene", JOURNAL OF VIROLOGICAL METHODS, vol. 174, no. 1, (2011), pages 22 - 28 *

Also Published As

Publication number Publication date
MY193417A (en) 2022-10-12
SG10201901735XA (en) 2019-03-28
JP2017527557A (ja) 2017-09-21
JP7113924B2 (ja) 2022-08-05
KR20170048396A (ko) 2017-05-08
KR102812180B1 (ko) 2025-05-23
CN112972668A (zh) 2021-06-18
KR20230134155A (ko) 2023-09-20
ZA201701077B (en) 2022-07-27
US10576141B2 (en) 2020-03-03
SG11201701506PA (en) 2017-03-30
JP2021063112A (ja) 2021-04-22
BR112017003908A2 (pt) 2018-02-27
AU2021209228A1 (en) 2021-08-19
EP3188752A2 (en) 2017-07-12
WO2016034678A2 (en) 2016-03-10
US11338030B2 (en) 2022-05-24
WO2016034678A3 (en) 2016-06-02
AU2015310909A1 (en) 2017-03-02
IL250552B (en) 2022-02-01
MX2017002791A (es) 2017-05-30
CN106999565A (zh) 2017-08-01
KR102736868B1 (ko) 2024-12-02
US20170304427A1 (en) 2017-10-26
UA126848C2 (uk) 2023-02-15
NZ729012A (en) 2023-12-22
IL250552A0 (en) 2017-03-30
JP6823586B2 (ja) 2021-02-03
US20200268872A1 (en) 2020-08-27
CA2959105C (en) 2023-10-17
CN106999565B (zh) 2021-03-05
CA2959105A1 (en) 2016-03-10
IL290052A (en) 2022-03-01

Similar Documents

Publication Publication Date Title
AU2015310909B2 (en) Recombinant modified vaccinia virus Ankara (MVA) filovirus vaccine
US11571471B2 (en) Recombinant modified vaccinia virus ankara (MVA) equine encephalitis virus vaccine
CA2879915C (en) Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
US20250387463A1 (en) Recombinant Modified saRNA (VRP) and Vaccinia Virus Ankara (MVA) Prime-Boost Regimen
EA039715B1 (ru) Филовирусная вакцина на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)
BR112017003908B1 (pt) Vacina contra filovírus de vírus de vaccinia modificado recombinante ankara (mva)
CA3009928C (en) Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
HK1205459B (en) Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)